**Supplemental Table 1**. Baseline Demographic Information in the All-Treated Patient Set

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Characteristic | PBO n = 101 | ASN  2.5 mg bid n = 97 | ASN 5 mg bid n = 113 | OLZ 15 mg qd n = 46 | All patients n = 357 |
| Sex, n (%) | | | | | |
| Female | 47 (46.5) | 39 (40.2) | 44 (38.9) | 18 (39.1) | 148 (41.5) |
| Race, n (%) | | | | | |
| White | 74 (73.3) | 67 (69.1) | 85 (75.2) | 29 (63.0) | 255 (71.4) |
| Black | 27 (26.7) | 29 (29.9) | 28 (24.8) | 16 (34.8) | 100 (28.0) |
| American Indian or Alaskan Native | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Asian | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Native Hawaiian or Other Pacific Islander | 0 (0.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) | 1 (0.3) |
| Multiracial | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.2) | 1 (0.3) |
| Age, years, mean (SD) | 41.4 (12.05) | 41.5 (10.79) | 39.1 (10.68) | 40.8 (11.15) | 40.6 (11.18) |
| PANSS total score,a mean (SD) | 93.4 (11.16) | 93.3 (11.10) | 95.8 (13.77) | 92.7 (10.47) | 94.1 (11.97) |
| CGI-S score,a mean (SD) | 4.8 (0.61) | 4.8 (0.64) | 4.9 (0.64) | 4.8 (0.61) | 4.8 (0.65) |
| EPS symptoms | | | | | |
| AIMS global score, mean (SD) | 0.1 (0.39) | 0.1 (0.49) | 0.1 (0.44) | 0.3 (0.89) | 0.1 (0.52) |
| BARS global score, mean (SD) | 0.2 (0.51) | 0.1 (0.41) | 0.1 (0.30) | 0.3 (0.61) | 0.2 (0.44) |
| SARS total score, mean (SD) | 1.0 (2.00) | 1.1 (2.09) | 1.0 (2.15) | 1.1 (2.19) | 1.1 (2.09) |
| AIMS, Abnormal Involuntary Movement Scale; ASN, asenapine; BARS, Barnes Akathisia Rating Scale; bid, twice daily; CGI-S, Clinical Global Impression-Severity; OLZ, olanzapine; PANSS, Positive and Negative Syndrome Scale; PBO, placebo; SARS, Simpson Angus Rating Scale; SD, standard deviation; qd, once daily.  aBased on the Full Analysis Set, which included 99 patients treated with placebo, 96 patients treated with ASN 2.5 mg bid, 111 patients treated with ASN 5 mg bid, and 45 patients treated with OLZ 15 mg qd. | | | | | |